

Vaccinia Virus B18R Recombinant Protein, eBioscience™

Product Details	
Size	5 µg
Species	Virus
Expression System	Insect
Amino acid sequence	Vaccinia Virus B18R, amino acids His-20-Glu351 (Accession # D01019)
Tag	His-tag
Molecular weight	60-65 kDa
Class	Recombinant
Type	Protein
Purity	>90% by SDS-PAGE
Endotoxin concentration	<0.01 ng/µg
Activity	ND50 < 800 pg/mL; as measured by the neutralization of 1 ng/mL mouse IFN-alpha 2 recombinant protein.
Conjugate	Unconjugated
Form	Liquid
Concentration	0.1 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.5, with 1% BSA
Contains	no preservative
Storage conditions	-80°C

Applications	Tested Dilution	Publications
Functional Assay (FN)	Assay-Dependent	-
Control (Ctrl)	Assay-Dependent	-
Miscellaneous PubMed (Misc)	-	5 Publications

Product Specific Information

Description: The B18R protein is a vaccinia virus-encoded receptor with specificity for mouse, human, rabbit, pig, rat, and cow type I interferons which has potent neutralizing activity. B18R that acts as a decoy receptor for Type I Interferons (IFN α , IFN β , IFN ϵ , k, t, d, z, w, v). B18R was recently identified to enable increased cell viability during RNA transfection protocols designed to convert human somatic donor cells into iPSCs via direct delivery of modified synthetic mRNAs for OCT4, SOX2, KLF4 and MYC (OSKM) and Lin28 with the aim to enable highly efficient reprogramming of somatic cells to pluripotency. This allows for re-directed differentiation toward a desired lineage while removing the risk of genomic integration and insertional mutagenesis inherent to DNA-bases methodologies and eliminates the need for virus-based approaches. iPSCs represent a widely available, non-controversial and practically infinite source of pluripotent cells.

The B18R protein is a type I interferon receptor encoded by the B18R gene of the Western Reserve vaccinia virus strain. The 60-65 kD glycoprotein is related to the interleukin-1 receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN-receptors, which belong to the class II cytokine receptor family. The B18R protein has a high affinity (KD, 174 pM) for human IFN alpha and, unlike other type I IFN receptors, has broad species specificity, binding to type I interferons of human, mouse, rat,

rabbit, pig, and cow. Among viral host response modifiers, the B18R protein is unique in that it exists as a soluble extracellular, as well as a cell surface protein, enabling blockage of both autocrine and paracrine IFN functions. The B18R protein has been shown to inhibit the antiviral potency of IFN-alpha1, IFN-alpha2, IFN-alpha-8/1/8, and IFN-omega on human cells. The soluble B18R protein is highly potent for neutralizing type I interferons, which include IFN-alpha, beta, delta, kappa. Please note effects on mouse IFNs vary from other species; it has been shown that B18R does not neutralize mouse IFN beta.

Applications Reported: Recombinant B18R is fully biologically active.

Applications Tested: This recombinant B18R protein (type I IFN receptor) has been tested in bioassay for neutralization of mouse and human interferons (alpha and beta).

Human IFN: Pre-incubation of recombinant human IFN alpha2a with 0.1 µg/mL B18R for 1 hr at RT was found to neutralize completely the activity of 1 ng/mL IFN alpha2a.

Mouse IFN: In an assay of EMCV infection of L929 cells, pre-incubation of recombinant mouse IFN alphaA with 250.0 picograms/mL B18R for 1 hr at RT was found to neutralize completely the activity of 5 pg/mL (1 Unit) mIFN alphaA. The ND50 of this protein, as measured by neutralization of Mouse IFN alpha 2 Recombinant Protein, is less than or equal to 800 pg/mL in the presence of 1 ng/mL Mouse IFN alpha 2. This corresponds to a specific activity of greater than or equal to 1.3 x 10⁶ Units/mg.

Source: Insect cells infected with baculovirus: amino acids His20-Glu 351 with a His-tag attached of Vaccinia Virus B18R accession # D01019.

Bioactivity: The ND50 of this protein, as measured by neutralization of Mouse IFN alpha 2 Recombinant Protein, is less than or equal to 800 pg/mL in the presence of 1 ng/mL Mouse IFN alpha 2. This corresponds to a specific activity of greater than or equal to 1.3 x 10⁶ Units/mg.

Endotoxin: Less than 0.01 ng/ug cytokine as determined by the LAL assay. Purity: >98% as determined by SDS-PAGE.

Molecular Weight: The polypeptide has a predicted molecular mass of 38,389. The DTT-reduced protein migrates as a 48 kDa polypeptide on SDS-PAGE due to glycosylation. The non-reduced protein migrates as a 46 kDa polypeptide on SDS-PAGE due to internal cystines.

Storage and handling: For best recovery, quick-spin vial prior to opening. Use in a sterile environment.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

5 References

Miscellaneous PubMed (5)

Clinical cancer research : an official journal of the American Association for Cancer Research

A Potent *In Vivo* Antitumor Efficacy of Novel Recombinant Type I Interferon.

Authors: Zhang KJ, Yin XF, Yang YQ, Li HL, Xu YN, Chen LY, Liu XJ, Yuan SJ, Fang XL, Xiao J, Wu S, Xu HN, Chu L, Katlinski KV, Katlinskaya YV, Guo RB, Wei GW, Wang DC, Liu XY, Fuchs SY

Species
Not Applicable

Dilution
Not Cited

Year
2017

Journal of virology

Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response.

Authors: Qu L, Murakami K, Broughman JR, Lay MK, Guix S, Tenge VR, Atmar RL, Estes MK

Species
Not Applicable

Dilution
Not Cited

Year
2016

[View more Misc references on thermofisher.com](#)

More applications with references on thermofisher.com

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.